Harvard Bioscience (HBIO) Operating Leases (2019 - 2026)

Harvard Bioscience (HBIO) has 8 years of Operating Leases data on file, last reported at $7.9 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $7.9 million, up 9.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.9 million (up 9.42% YoY), and the FY2025 annual result was $8.4 million, up 31.75% from the prior year.
• Operating Leases declined to $7.9 million in Q1 2026 per HBIO's latest filing, from $8.4 million in the prior quarter.
• Over five years, Operating Leases peaked at $8.8 million in Q2 2025 and troughed at $4.7 million in Q2 2024.
• A 5-year average of $6.8 million and a median of $6.8 million in 2023 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2023 and 2025: Operating Leases plunged 37.6% in 2023, then surged 87.1% in 2025.
• A 5-year view of Operating Leases shows it stood at $5.3 million in 2022, then dropped by 9.24% to $4.8 million in 2023, then jumped by 33.1% to $6.4 million in 2024, then soared by 31.75% to $8.4 million in 2025, then decreased by 5.9% to $7.9 million in 2026.
• Business Quant data shows HBIO's Operating Leases at $7.9 million in Q1 2026, $8.4 million in Q4 2025, and $8.8 million in Q3 2025.